Hisao Nojiri

Title: Hisao Nojiri: Innovator in Blood Treatment Methods

Introduction

Hisao Nojiri is a notable inventor based in Seattle, WA, who has made significant contributions to the field of biomedical research. He holds 2 patents that focus on innovative methods for blood treatment and cell growth stimulation. His work has the potential to impact therapeutic approaches in cancer treatment and cell biology.

Latest Patents

His latest patents include a blood treatment method that involves producing monoclonal antibodies targeting tumor-associated gangliosides. This method consists of several steps, including immunizing a host with tumor cells, boosting the host with a mixture of tumor cell membrane and purified gangliosides, and fusing immunized cells with myeloma cells to create hybridoma cells. The process culminates in the recovery of antibodies that bind to specific gangliosides. Another patent focuses on preparing de-N-acylated forms of glycosphingolipids, which involves hydrolyzing glycosphingolipids under mild alkaline conditions. This method aims to isolate substantially pure gangliosides containing de-N-acetyl-sialic acid from natural sources.

Career Highlights

Throughout his career, Hisao Nojiri has worked with esteemed organizations such as the Biomembrane Institute and Jichi Medical School. His experience in these institutions has allowed him to develop and refine his innovative techniques in the field of biomedical research.

Collaborations

Hisao Nojiri has collaborated with notable individuals in his field, including Sen-Itiroh Hakomori and Gustavo A Nores. These collaborations have contributed to the advancement of research in gangliosides and their applications in medicine.

Conclusion

Hisao Nojiri's contributions to blood treatment methods and cell growth stimulation highlight his role as an influential inventor in the biomedical field. His innovative patents and collaborations continue to pave the way for advancements in medical research and treatment options.